KR20150033678A - 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 - Google Patents

페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 Download PDF

Info

Publication number
KR20150033678A
KR20150033678A KR20157001888A KR20157001888A KR20150033678A KR 20150033678 A KR20150033678 A KR 20150033678A KR 20157001888 A KR20157001888 A KR 20157001888A KR 20157001888 A KR20157001888 A KR 20157001888A KR 20150033678 A KR20150033678 A KR 20150033678A
Authority
KR
South Korea
Prior art keywords
pain
disorder
disorders
disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20157001888A
Other languages
English (en)
Korean (ko)
Inventor
야누스 슈레이베르 라르센
마그누스 구스타프손
카르스텐 예센
Original Assignee
사니오나 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사니오나 에이피에스 filed Critical 사니오나 에이피에스
Publication of KR20150033678A publication Critical patent/KR20150033678A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR20157001888A 2012-06-26 2013-06-25 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도 Ceased KR20150033678A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664287P 2012-06-26 2012-06-26
US61/664,287 2012-06-26
DKPA201270368 2012-06-26
DKPA201270368 2012-06-26
PCT/EP2013/063193 WO2014001281A1 (en) 2012-06-26 2013-06-25 A phenyl triazole derivative and its use for modulating the gabaa receptor complex

Publications (1)

Publication Number Publication Date
KR20150033678A true KR20150033678A (ko) 2015-04-01

Family

ID=49782299

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157001888A Ceased KR20150033678A (ko) 2012-06-26 2013-06-25 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도

Country Status (10)

Country Link
US (2) US9206160B2 (https=)
EP (1) EP2877463B1 (https=)
JP (1) JP6224097B2 (https=)
KR (1) KR20150033678A (https=)
CN (1) CN104411699B (https=)
AU (1) AU2013283487C1 (https=)
CA (1) CA2876778A1 (https=)
IL (1) IL236041A (https=)
MX (1) MX357504B (https=)
WO (1) WO2014001281A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015233686B2 (en) * 2014-03-18 2019-07-11 Algiax Pharmaceuticals Gmbh 2-Cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
EP3858965B1 (en) * 2020-01-28 2022-05-11 The Procter & Gamble Company Cleaning product
EP4126858B1 (en) 2020-03-26 2026-03-18 Richter Gedeon Nyrt. Dihydro-2-pyrrolo[3,4-c]pyridine derivatives as gabaa a5 receptor modulators
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔３，４－ｃ〕嗒衍生物
US20230286946A1 (en) * 2020-08-05 2023-09-14 Boehringer Ingelheim International Gmbh Difluoromethyl-pyridin-2-yl triazoles
AU2022327398A1 (en) * 2021-08-12 2024-03-21 Shanghai SIMR Biotechnology Co., Ltd Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
US20260033761A1 (en) 2022-07-29 2026-02-05 Hoffmann-La Roche Inc. Characterisation of neurological dysfunction

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1042299A1 (en) * 1997-12-22 2000-10-11 Du Pont Pharmaceuticals Company Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors
EP1931661B1 (en) 2005-09-19 2008-11-19 F.Hoffmann-La Roche Ag Isoxazolo derivatives as gaba a alpha5 inverse agonists
WO2007042420A1 (en) 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
KR101103129B1 (ko) 2005-11-09 2012-01-04 에프. 호프만-라 로슈 아게 3-아릴-아이속사졸-4-카본일-벤조퓨란 유도체
RU2426731C2 (ru) 2005-12-23 2011-08-20 Ф. Хоффманн-Ля Рош Аг Производные арил-изоксазоло-4-ил-оксадиазола
BRPI0620773A2 (pt) 2005-12-27 2011-11-22 Hoffmann La Roche derivados de aril-isoxazol-4-il-imidazol
JP4864982B2 (ja) 2005-12-27 2012-02-01 エフ．ホフマン−ラ ロシュ アーゲー アリール−イソオキサゾール−４−イル−イミダゾ［１，５−ａ］ピリジン誘導体
MX2008014796A (es) 2006-05-31 2008-12-02 Hoffmann La Roche Derivados de aril-4-etinil-isoxazol.
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
JP5416103B2 (ja) 2007-06-22 2014-02-12 エフ．ホフマン−ラ ロシュ アーゲー イソオキサゾール−イミダゾール誘導体
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
UA100132C2 (en) 2007-12-04 2012-11-26 Ф. Хоффманн-Ля Рош Аг Isoxazolo-pyridine derivatives
WO2009071464A1 (en) 2007-12-04 2009-06-11 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US8227461B2 (en) 2009-04-30 2012-07-24 Hoffmann-La Roche Inc. Isoxazoles
AU2010244552A1 (en) 2009-05-05 2011-09-29 F. Hoffmann-La Roche Ag Isoxazole-pyrazole derivatives
MX2011011490A (es) 2009-05-05 2011-11-18 Hoffmann La Roche Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
WO2010127976A1 (en) 2009-05-05 2010-11-11 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
EP2427458B1 (en) 2009-05-05 2014-05-07 F.Hoffmann-La Roche Ag Isoxazole-pyridazine derivatives
MX2011011484A (es) 2009-05-07 2011-11-18 Hoffmann La Roche Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
MX341471B (es) 2010-11-05 2016-08-22 Hoffmann La Roche Uso de compuestos farmaceuticos activos para el tratamiento de estados patologicos del sistema nervioso central.
US8742097B2 (en) * 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US8466181B2 (en) 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds

Also Published As

Publication number Publication date
AU2013283487A1 (en) 2015-01-22
US20150152085A1 (en) 2015-06-04
EP2877463A1 (en) 2015-06-03
AU2013283487B2 (en) 2017-05-25
JP2015521642A (ja) 2015-07-30
AU2013283487C1 (en) 2018-01-18
US9206160B2 (en) 2015-12-08
US9931329B2 (en) 2018-04-03
CN104411699B (zh) 2017-06-13
JP6224097B2 (ja) 2017-11-01
US20160067234A1 (en) 2016-03-10
CN104411699A (zh) 2015-03-11
CA2876778A1 (en) 2014-01-03
WO2014001281A1 (en) 2014-01-03
IL236041A (en) 2016-09-29
EP2877463B1 (en) 2018-11-07
MX2014014871A (es) 2015-06-17
MX357504B (es) 2018-07-12
IL236041A0 (en) 2015-02-01

Similar Documents

Publication Publication Date Title
KR20150033678A (ko) 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
JP5290964B2 (ja) 新規１，４−ジアザ−ビシクロ［３．２．２］ノニルオキサジアゾリル誘導体及びそれらの医学的使用
US5998405A (en) Fused tropane-derivatives as neurotransmitter reuptake inhibitors
US9884848B2 (en) Phenyl triazole derivative and its use for modulating the GABAA receptor complex
JP2011500624A (ja) １，３，５−トリ置換されたトリアゾール誘導体
JP2009196997A (ja) 新規複素環式尿素誘導体およびドーパミンｄ３受容体リガンドとしてのそれらの使用
WO2014001279A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
JP2002531456A (ja) ８−アザビシクロ〔３．２．１〕オクト−２−エン及び−オクタン誘導体
WO2014001278A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001280A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
DE60216753T2 (de) Heterocyclische harnstoffderivate und deren verwendung als dopamine d3 receptor liganden
JP4588444B2 (ja) ジアザビシクロノナン及び−デカン誘導体並びにこれをオピオイドレセプターリガンドとして使用する方法
RU2107686C1 (ru) Производное 3-оксадиазолил-5,6,7,8-тетрагидро-1,6-нафтиридина и производное 5,6,7,8-тетрагидро-1,6-нафтиридина
JP5712135B2 (ja) ベンゾイミダゾール誘導体及びｇａｂａａレセプター複合体を調節するためのそれらの使用
TW202330518A (zh) 作為ＧＡＢＡＡ α５受體調節劑之雙環胺衍生物
JP2006522069A (ja) ベンズイミダゾール誘導体及びこれをｇａｂａａ受容体複合体をモジュレートするために使用する方法
JP2025530734A (ja) 神経障害の治療のためのヘテロ芳香族化合物
JP2011513461A (ja) ニコチン性アセチルコリン受容体モジュレーターとして有用な新規な１，４−ジアザ−ビシクロ［３．２．１］オクタン誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000